Clinical Trial Update: PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for CX-2029 in solid tumors and DLBCL completed; aims to identify safe and active dose levels.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Esophageal Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• CX-2029

Snippet

Sponsor: CytomX Therapeutics | Conditions: Solid Tumor, Adult, Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED